Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 14/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | PRKDC | P78527 | 5/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRE | P78334 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL27784235 | 0.87 | ATR (0.32) | ATRTDP1PRKDCALDH1A1 | |
| SCHEMBL12466450 | 0.84 | PDPK1 (0.39) | ATRPRKDCALDH1A1SMN1; SMN2ATM | |
| SCHEMBL3374259 | 0.83 | CDK5 (0.43) | ATRTDP1PRKDCALDH1A1MAPT | |
| Lithium Ion SCHEMBL19743866 | 0.81 | ATR (0.33) | ATRPRKDC | |
| SCHEMBL29804434 | 0.79 | NPSR1 (0.47) | ATRPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL3003587 | 0.79 | NPSR1 (0.47) | ATRPRKDCALDH1A1SMN1; SMN2 | |
| Calcium SCHEMBL30481734 | 0.79 | ALDH1A1 (0.40) | TDP1PTGS1PTGS2ALDH1A1MAPT | |
| SCHEMBL29054943 | 0.79 | ALDH1A1 (0.40) | TDP1PTGS1PTGS2ALDH1A1MAPT | |
| SCHEMBL10256130 | 0.79 | PLAU (0.46) | ATRTDP1PRKDCGABRPGABRD | |
| SCHEMBL2112207 | 0.78 | ATR (0.40) | ATRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113234029-B | Synthesis method of 2-amino-3, 5-dihalogen pyrazine | 白银康寓信生物科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-113234029-A | Synthesis method of 2-amino-3, 5-dihalogen pyrazine | 白银康寓信生物科技有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-10759785-B2 | Compounds | Enterprise Therapeutics Limited (GB) | 2020-09-01 | — | — | US | disclosed |
| EP-3472154-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2020-08-12 | — | — | EP | disclosed |
| US-20190233402-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2019-08-01 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| EP-1778687-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | STRUCTURAL GENOMIX, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| WO-2006015124-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1623216-A2 | COMPOUND LIBRARIES AND METHODS FOR DRUG DISCOVERY | SGX Pharmaceuticals, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040265909-A1 | Compound libraries and methods for drug discovery | SGX PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004092727-A2 | COMPOUND LIBRARIES AND METHODS FOR DRUG DISCOVERY | STRUCTURAL GENOMIX, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | MAP3K20, TTK, MAP3K19 | ATR 713/4885TDP1 1841/4885PRKDC 124/4885 |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | ATR 713/4885TDP1 1841/4885PRKDC 124/4885 |
| US-20190233402-A1 | COMPOUNDS | CFTR, NHERF1, SCNN1A | ATR 3410/4885TDP1 4432/4885PRKDC 4869/4885 |
| US-10759785-B2 | Compounds | CFTR, NHERF1, SCNN1A | ATR 3410/4885TDP1 4432/4885PRKDC 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.